Aurinia Pharmaceuticals (AUPH) Net Margin (2019 - 2026)

Aurinia Pharmaceuticals has reported Net Margin for 8 years, with the latest figure at 44.21% in Q1 2026.

• For the quarter ending Q1 2026, Net Margin rose 683.0% year-over-year to 44.21%; the trailing twelve-month figure through Mar 2026 stood at 99.96% (up 8384.0% YoY), and the FY2025 full-year result was 101.45%, up 9900.0% from the prior year.
• Net Margin for Q1 2026 stood at 44.21%, down from 273.3% in the prior quarter.
• The five-year high for Net Margin was 273.3% in Q4 2025, with the low at 174.01% in Q1 2022.
• Historically, Net Margin has averaged 9.63% across 5 years, with a median of 16.12% in 2022.
• Annual changes were most pronounced in 2022 — Net Margin soared 533791 bps — and 2023, when it plunged 855 bps.
• Aurinia Pharmaceuticals' Net Margin stood at 91.5% in 2022, then surged by 35 bps to 59.58% in 2023, then surged by 104 bps to 2.47% in 2024, then soared by 10977 bps to 273.3% in 2025, then sank by 84 bps to 44.21% in 2026.
• The last three Net Margin figures came in at 44.21% (Q1 2026), 273.3% (Q4 2025), and 42.95% (Q3 2025), per Business Quant data.